Liquidia Corporation (LQDA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $62.88, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606.
Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH and PH-ILD in May 2025, and promoting Treprostinil Injection (generic parenteral treprostinil) under a profit-sharing arrangement with Sandoz. Revenue is... Read more
Sell if holding. At $62.88, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Liquidia Corporation
Latest news
- NEWS Liquidia(LQDA.US) Officer Sells US$3.07 Million in Common Stock - Moomoo — Moomoo negative
- NEWS Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock - MarketBeat — MarketBeat negative
- NEWS Liquidia CEO Roger Jeffs sells $3.07m in company stock - Investing.com — Investing.com negative
- NEWS Liquidia (NASDAQ:LQDA) Raised to "Strong-Buy" at Zacks Research - MarketBeat — MarketBeat positive
- NEWS Liquidia (LQDA) Is Up 7.8% After EPS, Revenue Beat Forecasts And Insider 10b5-1 Sales - What's Changed - simplywall.st — simplywall.st positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYUTREPIA10-K Item 1A: 'We are primarily dependent on the success of YUTREPIA, for which we recently received FDA approval for the treatment of PAH and PH-ILD'
- HIGHpipelineL60610-K Item 1A: 'our planned pivotal clinical trial of L606, may not be successful and delays in such preclinical studies or clinical trials may cause our costs to increase'
- HIGHSuppliersingle suppliers for YUTREPIA active ingredient, device, encapsulation and packaging10-K Item 1A: 'single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the drug product and device for L606'
- HIGHcounterpartySandoz10-K Item 1A: 'Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection and is dependent on Sandoz to manufacture and supply Treprostinil Injection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $62.88, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $59.53. Score 5.2/10, moderate confidence.
Take-profit target: $65.44 (+2.2% upside). Prior stop was $59.53. Stop-loss: $59.53.
Concentration risk — Product: YUTREPIA; Concentration risk — Pipeline: L606; Analyst target reached - limited upside remaining.
Liquidia Corporation trades at a P/E of 375.9 (forward 11.5). TrendMatrix value score: 4.4/10. Verdict: Sell.
14 analysts cover LQDA with a consensus score of 4.4/5. Average price target: $66.
What does Liquidia Corporation do?Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH...
Liquidia is a biopharmaceutical company commercializing YUTREPIA (treprostinil inhalation powder), FDA-approved for PAH and PH-ILD in May 2025, and promoting Treprostinil Injection (generic parenteral treprostinil) under a profit-sharing arrangement with Sandoz. Revenue is derived from YUTREPIA sales and the Sandoz partnership; the company has an accumulated deficit of $626 million and achieved first profitability in Q3/Q4 2025.